Filing Details
- Accession Number:
- 0001567619-19-021887
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-19 17:03:13
- Reporting Period:
- 2019-11-15
- Accepted Time:
- 2019-11-19 17:03:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1012477 | Avadel Pharmaceuticals Plc | AVDL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1517718 | Michael Geoffrey Glass | Block 10-1, Blanchardstown Corporate Park, Ballycoolin Dublin L2 15 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Adss | Acquisiton | 2019-11-15 | 5,000 | $4.99 | 32,900 | No | 4 | P | Direct | |
| Adss | Acquisiton | 2019-11-18 | 15,000 | $4.99 | 47,900 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Adss | Stock Option (right to buy) | $2.03 | 2029-08-07 | 60,000 | 60,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2029-08-07 | 60,000 | 60,000 | Direct |
Footnotes
- The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.
- The price reported in Column 4 is a weighted average price. These ADSs were purchased in multiple transactions at prices ranging from $4.95 to $5.04, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs purchased at each separate price within the ranges set forth in this footnote (3).
- Options become exercisable as to 20,000 ADSs on each of the first three anniversaries after the 08/07/2019 grant date.
Billionaire Hedge Funds
